{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:04:58Z","timestamp":1789844698516,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-000934"],"award-info":[{"award-number":["MJFF-000934"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-000934"],"award-info":[{"award-number":["MJFF-000934"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-000934"],"award-info":[{"award-number":["MJFF-000934"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-000934"],"award-info":[{"award-number":["MJFF-000934"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-000934"],"award-info":[{"award-number":["MJFF-000934"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-000934"],"award-info":[{"award-number":["MJFF-000934"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-000934"],"award-info":[{"award-number":["MJFF-000934"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A hallmark of Parkinson\u2019s disease (PD) is the progressive neurodegeneration associated with soluble oligomeric and fibrillar forms of misfolded \u03b1-synuclein (\u03b1-syn). In this study, all-\n                    <jats:sc>d<\/jats:sc>\n                    -enantiomeric peptide ligands are presented that bind monomeric \u03b1-syn with high affinity, stabilize its physiological monomeric status, prevent aggregation and dissolve existing aggregates. This \u201cantiprionic\u201d mode of action directly targets pathogenic aggregated particles. Using mirror-image phage display on\n                    <jats:sc>d<\/jats:sc>\n                    -enantiomeric full-length \u03b1-syn, SVD-1 and SVD-1a were identified, showing a delay of aggregation and reduction of aggregate formation in both de novo and seeded models. Picomolar KDs were confirmed by SPR, where a highly dynamic interaction mode was verified by PRE-NMR. SVD-1a also reduced the toxicity and intracellular seeding of \u03b1-syn fibrils in cell culture by disassembling them into monomers, as confirmed by atomic force microscopy and dynamic light scattering. These results support SVD-1a as a promising lead compound for the treatment of Parkinson\u2019s disease.\n                  <\/jats:p>","DOI":"10.1038\/s41531-025-01132-7","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T13:41:12Z","timestamp":1758548472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Direct disassembly of \u03b1-syn preformed fibrils into \u03b1-syn monomers by an all-D-peptide"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7036-6927","authenticated-orcid":false,"given":"Marc","family":"Sevenich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Kass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madita","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Aghabashlou Saisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Tusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5151-6424","authenticated-orcid":false,"given":"Tatsiana","family":"Kupreichyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5416","authenticated-orcid":false,"given":"Wolfgang","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6725-0755","authenticated-orcid":false,"given":"Antje","family":"Willuweit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7390","authenticated-orcid":false,"given":"Janine","family":"Kutzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils-Alexander","family":"Lakomek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luitgard","family":"Nagel-Steger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-5027","authenticated-orcid":false,"given":"Lothar","family":"Gremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcltekin","family":"Tamg\u00fcney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine","family":"Mohrl\u00fcder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","volume":"47","author":"K Wakabayashi","year":"2013","unstructured":"Wakabayashi, K. et al. The Lewy body in Parkinson\u2019s disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495\u2013508 (2013).","journal-title":"Mol. Neurobiol."},{"key":"1132_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"1132_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jchemneu.2010.12.001","volume":"42","author":"FR Cheng","year":"2011","unstructured":"Cheng, F. R., Vivacqua, G. & Yu, S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J. Chem. Neuroanat. 42, 242\u2013248 (2011).","journal-title":"J. Chem. Neuroanat."},{"key":"1132_CR4","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","volume":"8","author":"L Maroteaux","year":"1988","unstructured":"Maroteaux, L., Campanelli, J. T. & Scheller, R. H. Synuclein\u2014a neuron-specific protein localized to the nucleus and presynaptic nerve-terminal. J. Neurosci. 8, 2804\u20132815 (1988).","journal-title":"J. Neurosci."},{"key":"1132_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","volume":"12","author":"CR Fields","year":"2019","unstructured":"Fields, C. R., Bengoa-Vergniory, N. & Wade-Martins, R. Targeting alpha-synuclein as a therapy for Parkinson\u2019s disease. Front. Mol. Neurosci. 12, 299 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"1132_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","volume":"134","author":"N Bengoa-Vergniory","year":"2017","unstructured":"Bengoa-Vergniory, N., Roberts, R. F., Wade-Martins, R. & Alegre-Abarrategui, J. Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 134, 819\u2013838 (2017).","journal-title":"Acta Neuropathol."},{"key":"1132_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fnins.2016.00408","volume":"10","author":"M Ingelsson","year":"2016","unstructured":"Ingelsson, M. Alpha-synuclein oligomers-neurotoxic molecules in Parkinson\u2019s disease and other Lewy body disorders. Front. Neurosci. 10, 408 (2016).","journal-title":"Front. Neurosci."},{"key":"1132_CR8","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1021\/acs.chemrev.1c00196","volume":"121","author":"D Willbold","year":"2021","unstructured":"Willbold, D., Strodel, B., Schr\u00f6der, G. F., Hoyer, W. & Heise, H. Amyloid-type protein aggregation and prion-like properties of amyloids. Chem. Rev. 121, 8285\u20138307 (2021).","journal-title":"Chem. Rev."},{"key":"1132_CR9","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","volume":"25","author":"HJ Lee","year":"2005","unstructured":"Lee, H. J., Patel, S. & Lee, S. J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016\u20136024 (2005).","journal-title":"J. Neurosci."},{"key":"1132_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.nbd.2017.11.004","volume":"109","author":"L Volpicelli-Daley","year":"2018","unstructured":"Volpicelli-Daley, L. & Brundin, P. Editorial: Pathogenic templating proteins in neurodegenerative disease. Neurobiol. Dis. 109, 175\u2013177 (2018).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR11","doi-asserted-by":"publisher","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","volume":"112","author":"SB Prusiner","year":"2015","unstructured":"Prusiner, S. B. et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with Parkinsonism. Proc. Natl Acad. Sci. USA 112, E5308\u2013E5317 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR12","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/molecules24122237","volume":"24","author":"D Willbold","year":"2019","unstructured":"Willbold, D. & Kutzsche, J. Do we need anti-prion compounds to treat Alzheimer\u2019s disease?. Molecules 24, 2237 (2019).","journal-title":"Molecules"},{"key":"1132_CR13","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s12035-018-1209-3","volume":"56","author":"S Schemmert","year":"2019","unstructured":"Schemmert, S. et al. A oligomer elimination restores cognition in transgenic Alzheimer\u2019s mice with full-blown pathology. Mol. Neurobiol. 56, 2211\u20132223 (2019).","journal-title":"Mol. Neurobiol."},{"key":"1132_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16565-1","volume":"7","author":"T van Groen","year":"2017","unstructured":"van Groen, T. et al. The A beta oligomer eliminating d-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci. Rep. 7, 16275 (2017).","journal-title":"Sci. Rep."},{"key":"1132_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nbd.2018.10.021","volume":"124","author":"S Schemmert","year":"2019","unstructured":"Schemmert, S. et al. Deceleration of the neurodegenerative phenotype in pyroglutamate-A\u03b2 accumulating transgenic mice by oral treatment with the A\u03b2 oligomer eliminating compound RD2. Neurobiol. Dis. 124, 36\u201345 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3390\/molecules24112129","volume":"24","author":"T Zhang","year":"2019","unstructured":"Zhang, T., Loschwitz, J., Strodel, B., Nagel-Steger, L. & Willbold, D. Interference with amyloid-nucleation by transient ligand interaction. Molecules 24, 2129 (2019).","journal-title":"Molecules"},{"key":"1132_CR17","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.xcrm.2022.100630","volume":"3","author":"B Kass","year":"2022","unstructured":"Kass, B. et al. A\u03b2 oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo. Cell Rep. Med. 3, 100630 (2022).","journal-title":"Cell Rep. Med."},{"key":"1132_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41993-6","volume":"9","author":"A Elfgen","year":"2019","unstructured":"Elfgen, A. et al. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-beta oligomers. Sci. Rep. 9, 5715 (2019).","journal-title":"Sci. Rep."},{"key":"1132_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11095-015-1791-2","volume":"33","author":"LHE Leithold","year":"2016","unstructured":"Leithold, L. H. E. et al. Pharmacokinetic properties of a novel d-peptide developed to be therapeutically active against toxic \u03b2-amyloid oligomers. Pharm. Res. 33, 328\u2013336 (2016).","journal-title":"Pharm. Res."},{"key":"1132_CR20","doi-asserted-by":"publisher","first-page":"11923","DOI":"10.1073\/pnas.1811520115","volume":"115","author":"C Allolio","year":"2018","unstructured":"Allolio, C. et al. Arginine-rich cell-penetrating peptides induce membrane multilamellarity and subsequently enter via formation of a fusion pore. Proc. Natl Acad. Sci. USA 115, 11923\u201311928 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR21","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1113\/JP271968","volume":"594","author":"TJ Kaufmann","year":"2016","unstructured":"Kaufmann, T. J., Harrison, P. M., Richardson, M. J. E., Pinheiro, T. J. T. & Wall, M. J. Intracellular soluble alpha-synuclein oligomers reduce pyramidal cell excitability. J. Physiol.-Lond. 594, 2751\u20132772 (2016).","journal-title":"J. Physiol.-Lond."},{"key":"1132_CR22","doi-asserted-by":"publisher","first-page":"7671","DOI":"10.1073\/pnas.1315346111","volume":"111","author":"AK Buell","year":"2014","unstructured":"Buell, A. K. et al. Solution conditions determine the relative importance of nucleation and growth processes in \u03b1-synuclein aggregation. Proc. Natl Acad. Sci. USA 111, 7671\u20137676 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR23","doi-asserted-by":"publisher","first-page":"105086","DOI":"10.1016\/j.nbd.2020.105086","volume":"146","author":"ST Kumar","year":"2020","unstructured":"Kumar, S. T. et al. How specific are the conformation-specific alpha-synuclein antibodies? Characterization and validation of 16 alpha-synuclein conformation-specific antibodies using well-characterized preparations of alpha-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol. Dis. 146, 105086 (2020).","journal-title":"Neurobiol. Dis."},{"key":"1132_CR24","doi-asserted-by":"publisher","first-page":"E4949","DOI":"10.1073\/pnas.1513426112","volume":"112","author":"AL Woerman","year":"2015","unstructured":"Woerman, A. L. et al. Propagation of prions causing synucleinopathies in cultured cells. Proc. Natl Acad. Sci. USA 112, E4949\u2013E4958 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR25","doi-asserted-by":"publisher","first-page":"a024588","DOI":"10.1101\/cshperspect.a024588","volume":"8","author":"AL Woerman","year":"2018","unstructured":"Woerman, A. L. et al. \u03b1-synuclein: multiple system atrophy prions. Cold Spring Harb. Perspect. Med. 8, a024588 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1132_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1073\/pnas.1719369115","volume":"115","author":"AL Woerman","year":"2017","unstructured":"Woerman, A. L. et al. Familial Parkinson\u2019s point mutation abolishes multiple system atrophy prion replication. Proc. Natl Acad. Sci. USA 115, 409\u2013414 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR27","doi-asserted-by":"publisher","first-page":"eaat8462","DOI":"10.1126\/scitranslmed.aat8462","volume":"11","author":"A Aoyagi","year":"2019","unstructured":"Aoyagi, A. et al. A\u03b2 and tau prion-like activities decline with longevity in the Alzheimer\u2019s disease human brain. Sci. Transl. Med. 11, eaat8462 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1132_CR28","doi-asserted-by":"crossref","unstructured":"Brutscher, B. et al. NMR methods for the study of instrinsically disordered proteins structure, dynamics, and interactions: general overview and practical guidelines. Adv. Exp. Med. Biol. 870, 49\u2013122 (2015).","DOI":"10.1007\/978-3-319-20164-1_3"},{"key":"1132_CR29","doi-asserted-by":"crossref","unstructured":"Prestel, A., Bugge, K., Staby, L., Hendus-Altenburger, R. & Kragelund, B. B. Characterization of dynamic IDP complexes by NMR spectroscopy. Methods Enzymol. 611, 193\u2013226 (2018).","DOI":"10.1016\/bs.mie.2018.08.026"},{"key":"1132_CR30","doi-asserted-by":"publisher","first-page":"16464","DOI":"10.1021\/acs.jmedchem.1c00632","volume":"64","author":"EV Bocharov","year":"2021","unstructured":"Bocharov, E. V. et al. All-d enantiomeric peptide D3 designed for Alzheimer\u2019s disease treatment dynamically interacts with membrane-bound amyloid-\u03b2 precursors. J. Med Chem. 64, 16464\u201316479 (2021).","journal-title":"J. Med Chem."},{"key":"1132_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature25762","volume":"555","author":"A Borgia","year":"2018","unstructured":"Borgia, A. et al. Extreme disorder in an ultrahigh-affinity protein complex. Nature 555, 61 (2018).","journal-title":"Nature"},{"key":"1132_CR32","doi-asserted-by":"publisher","first-page":"7515","DOI":"10.1002\/anie.201701883","volume":"56","author":"SW Wu","year":"2017","unstructured":"Wu, S. W. et al. The dynamic multisite interactions between two intrinsically disordered proteins. Angew. Chem.-Int. Ed. 56, 7515\u20137519 (2017).","journal-title":"Angew. Chem.-Int. Ed."},{"key":"1132_CR33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1042\/BST20130232","volume":"41","author":"GM Clore","year":"2013","unstructured":"Clore, G. M. Seeing the invisible by paramagnetic and diamagnetic NMR. Biochem. Soc. Trans. 41, 1343\u20131354 (2013).","journal-title":"Biochem. Soc. Trans."},{"key":"1132_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.sbi.2007.08.013","volume":"17","author":"GM Clore","year":"2007","unstructured":"Clore, G. M., Tang, C. & Iwahara, J. Elucidating transient macromolecular interactions using paramagnetic relaxation enhancement. Curr. Opin. Struct. Biol. 17, 603\u2013616 (2007).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"1132_CR35","doi-asserted-by":"publisher","first-page":"12456","DOI":"10.1073\/pnas.1615342113","volume":"113","author":"L Deshmukh","year":"2016","unstructured":"Deshmukh, L., Louis, J. M., Ghirlando, R. & Clore, G. M. Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations. Proc. Natl Acad. Sci. USA 113, 12456\u201312461 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR36","doi-asserted-by":"publisher","first-page":"23239","DOI":"10.1002\/anie.202010006","volume":"59","author":"A Di Savino","year":"2020","unstructured":"Di Savino, A. et al. Efficient encounter complex formation and electron transfer to cytochrome c peroxidase with an additional, distant electrostatic binding site. Angew. Chem. Int. Ed. Engl. 59, 23239\u201323243 (2020).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1132_CR37","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/nature04673","volume":"440","author":"J Iwahara","year":"2006","unstructured":"Iwahara, J. & Clore, G. M. Detecting transient intermediates in macromolecular binding by paramagnetic NMR. Nature 440, 1227\u20131230 (2006).","journal-title":"Nature"},{"key":"1132_CR38","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/nature06232","volume":"449","author":"C Tang","year":"2007","unstructured":"Tang, C., Schwieters, C. D. & Clore, G. M. Open-to-closed transition in apo maltose-binding protein observed by paramagnetic NMR. Nature 449, 1078\u20131082 (2007).","journal-title":"Nature"},{"key":"1132_CR39","doi-asserted-by":"publisher","first-page":"18945","DOI":"10.1073\/pnas.0603551103","volume":"103","author":"AN Volkov","year":"2006","unstructured":"Volkov, A. N., Worrall, J. A. R., Holtzmann, E. & Ubbink, M. Solution structure and dynamics of the complex between cytochrome c and cytochrome c peroxidase determined by paramagnetic NMR. Proc. Natl Acad. Sci. USA 103, 18945\u201318950 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38070-4","volume":"13","author":"T Ohgita","year":"2023","unstructured":"Ohgita, T. et al. Intramolecular interaction kinetically regulates fibril formation by human and mouse \u03b1-synuclein. Sci. Rep. 13, 10885 (2023).","journal-title":"Sci. Rep."},{"key":"1132_CR41","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.bpj.2009.12.4290","volume":"98","author":"S Nath","year":"2010","unstructured":"Nath, S., Meuvis, J., Hendrix, J., Carl, S. A. & Engelborghs, Y. Early aggregation steps in \u03b1-synuclein as measured by FCS and FRET: evidence for a contagious conformational change. Biophys. J. 98, 1302\u20131311 (2010).","journal-title":"Biophys. J."},{"key":"1132_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.sbi.2021.03.015","volume":"70","author":"HJ Dyson","year":"2021","unstructured":"Dyson, H. J. & Wright, P. E. NMR illuminates intrinsic disorder. Curr. Opin. Struct. Biol. 70, 44\u201352 (2021).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"1132_CR43","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1073\/pnas.1512799112","volume":"112","author":"M Arai","year":"2015","unstructured":"Arai, M., Sugase, K., Dyson, H. J. & Wright, P. E. Conformational propensities of intrinsically disordered proteins influence the mechanism of binding and folding. Proc. Natl Acad. Sci. USA 112, 9614\u20139619 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR44","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner, J. et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 125, 795\u2013813 (2013).","journal-title":"Acta Neuropathol."},{"key":"1132_CR45","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1073\/pnas.1804198115","volume":"115","author":"J Pujols","year":"2018","unstructured":"Pujols, J. et al. Small molecule inhibits \u03b1-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc. Natl Acad. Sci. USA 115, 10481\u201310486 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1132_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46538-8","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. HTRA1 disaggregates \u03b1-synuclein amyloid fibrils and converts them into non-toxic and seeding incompetent species. Nat. Commun. 15, 2436 (2024).","journal-title":"Nat. Commun."},{"key":"1132_CR47","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1042\/BST20120096","volume":"40","author":"A Binolfi","year":"2012","unstructured":"Binolfi, A., Theillet, F. X. & Selenko, P. Bacterial in-cell NMR of human alpha-synuclein: a disordered monomer by nature?. Biochem. Soc. Trans. 40, 950\u2013U292 (2012).","journal-title":"Biochem. Soc. Trans."},{"key":"1132_CR48","doi-asserted-by":"publisher","first-page":"e15801","DOI":"10.1371\/journal.pone.0015801","volume":"5","author":"M Johnson","year":"2010","unstructured":"Johnson, M., Coulton, A. T., Geeves, M. A. & Mulvihill, D. P. Targeted amino-terminal acetylation of recombinant proteins in E. coli. PLoS ONE 5, e15801 (2010).","journal-title":"PLoS ONE"},{"key":"1132_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0022-2836(02)00775-1","volume":"322","author":"W Hoyer","year":"2002","unstructured":"Hoyer, W. et al. Dependence of \u03b1-synuclein aggregate morphology on solution conditions. J. Mol. Biol. 322, 383\u2013393 (2002).","journal-title":"J. Mol. Biol."},{"key":"1132_CR50","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s00216-019-01714-4","volume":"411","author":"R Barderas","year":"2019","unstructured":"Barderas, R. & Benito-Pena, E. The 2018 Nobel Prize in Chemistry: phage display of peptides and antibodies. Anal. Bioanal. Chem. 411, 2475\u20132479 (2019).","journal-title":"Anal. Bioanal. Chem."},{"key":"1132_CR51","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1039\/b904138a","volume":"5","author":"SA Funke","year":"2009","unstructured":"Funke, S. A. & Willbold, D. Mirror image phage display\u2014a method to generate d-peptide ligands for use in diagnostic or therapeutical applications. Mol. Biosyst. 5, 783\u2013786 (2009).","journal-title":"Mol. Biosyst."},{"key":"1132_CR52","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/cbic.200300570","volume":"4","author":"K Wiesehan","year":"2003","unstructured":"Wiesehan, K. & Willbold, D. Mirror-image phage display: aiming at the mirror. ChemBioChem 4, 811\u2013815 (2003).","journal-title":"ChemBioChem"},{"key":"1132_CR53","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1021\/acschemneuro.1c00253","volume":"12","author":"K Santur","year":"2021","unstructured":"Santur, K. et al. Ligand-induced stabilization of the native human superoxide dismutase 1. ACS Chem. Neurosci. 12, 2520\u20132528 (2021).","journal-title":"ACS Chem. Neurosci."},{"key":"1132_CR54","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/biomedicines10020441","volume":"10","author":"M Sevenich","year":"2022","unstructured":"Sevenich, M. et al. Phage display-derived compounds displace hACE2 from its complex with SARS-CoV-2 spike protein. Biomedicines 10, 441 (2022).","journal-title":"Biomedicines"},{"key":"1132_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/biom12020157","volume":"12","author":"PE Kolkwitz","year":"2022","unstructured":"Kolkwitz, P. E., Mohrlueder, J. & Willbold, D. Inhibition of polyglutamine misfolding with d-enantiomeric peptides identified by mirror image phage display selection. Biomolecules 12, 157 (2022).","journal-title":"Biomolecules"},{"key":"1132_CR56","first-page":"100166","volume":"4","author":"T Altendorf","year":"2024","unstructured":"Altendorf, T., Mohrl\u00fcder, J. & Willbold, D. TSAT: efficient evaluation software for NGS data of phage\/mirror-image phage display selections. Biophys. Rep. 4, 100166 (2024).","journal-title":"Biophys. Rep."},{"key":"1132_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bioinformatics\/btv522","volume":"32","author":"A Krejci","year":"2016","unstructured":"Krejci, A., Hupp, T. R., Lexa, M., Vojtesek, B. & Muller, P. Hammock: a hidden Markov model-based peptide clustering algorithm to identify protein-interaction consensus motifs in large datasets. Bioinformatics 32, 9\u201316 (2016).","journal-title":"Bioinformatics"},{"key":"1132_CR58","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1021\/bi002555c","volume":"40","author":"L Nielsen","year":"2001","unstructured":"Nielsen, L. et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 40, 6036\u20136046 (2001).","journal-title":"Biochemistry"},{"key":"1132_CR59","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/prot.20449","volume":"59","author":"WF Vranken","year":"2005","unstructured":"Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins: Struct., Funct. Genet. 59, 687\u2013696 (2005).","journal-title":"Proteins: Struct., Funct. Genet."},{"key":"1132_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnmrs.2013.02.001","volume":"73","author":"MP Williamson","year":"2013","unstructured":"Williamson, M. P. Using chemical shift perturbation to characterise ligand binding. Prog. Nucl. Magn. Reson. Spectrosc. 73, 1\u201316 (2013).","journal-title":"Prog. Nucl. Magn. Reson. Spectrosc."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01132-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01132-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01132-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:20:53Z","timestamp":1758720053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01132-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01132-7","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S., J.M., and D.W. are co-inventors of patents covering the composition of matter of SVD-peptides. D.W. and A.W. are co-founders and shareholders of the company \u201cPriavoid GmbH, D\u00fcsseldorf, Germany\u201d, which is planning to further develop the SVD-peptides. M.S., B.K., and A.W. are employees of Priavoid GmbH. They declare that this has not influenced the evaluation and interpretation of experiments. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}